ArticleCancers2020
The Role of Transient Receptor Potential Melastatin 7 (TRPM7) in Cell Viability: A Potential Target to Suppress Breast Cancer Cell Cycle.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 102 citations in OpenAlex.
- The expression of glial cell-derived neurotrophic factor in the hippocampal tissue of rats with vascular dementia and its correlation with molecular pathways involved in learning and memory impairment.Journal of bioenergetics and biomembranes · 2026Article
- SCN3B is an Anti-breast Cancer Molecule with Migration Inhibition Effect.Biochemical genetics · 2026Article
- Immune regulation of Chidamide-induced Linc01010 accumulation in breast cancer cell death.World journal of clinical oncology · 2025Article
- Proteomics analysis reveals FEN1 as a promising therapeutic target against small cell neuroendocrine carcinoma of the cervix.Scientific reports · 2025Article
- SIAH2-AS1 stimulates breast cancer cell proliferation and migration via the Wnt/β-catenin signaling pathway.Scientific reports · 2025Article
- Sialylated IgG expressed in triple-negative breast cancer cells promotes cancer progression by promoting glycolysis.Breast cancer research : BCR · 2025Article
- Lidocaine-A Promising Candidate for the Treatment of Cancer-Induced Bone Pain: A Narrative Review.Advances in therapy · 2025Review
- Targeting Tumor Microenvironment Interactions in Chronic Lymphocytic Leukemia Using Leukotriene Inhibitors.International journal of molecular sciences · 2025Article
- Technical and Biological Biases in Bulk Transcriptomic Data Mining for Cancer Research.Journal of Cancer · 2025Review
- EFTUD2 is a promising diagnostic and prognostic indicator involved in the tumor immune microenvironment and glycolysis of lung adenocarcinoma.Frontiers in oncology · 2025Article
- Gene expression profiling for the diagnosis of male breast cancer.BMC cancer · 2024Article
- TRPM channels in human cancers: regulatory mechanism and therapeutic prospects.Biomarker research · 2024Review
- Pan-cancer genetic profiles of mitotic DNA integrity checkpoint protein kinases.Cancer biomarkers : section A of Disease markers · 2024Article
- Article
- TROP2 promotes the proliferation of triple-negative breast cancer cells via calcium ion-dependent ER stress signaling pathway.Cell biochemistry and biophysics · 2024Article
- Voltage-gated sodium channels in cancers.Biomarker research · 2024Review
- The p53-mediated cell cycle regulation is a potential mechanism for emodin-suppressing osteosarcoma cells.Heliyon · 2024Article
- The Role of TRPM7 in Oncogenesis.International journal of molecular sciences · 2024Review
- Quercetin suppresses cell viability in triple-negative breast cancer by targeting ORM2.American journal of cancer research · 2024Article
- Chebulinic acid isolated from aqueous extracts ofFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The divalent cation-selective channel transient receptor potential melastatin 7 (TRPM7) channel was shown to affect the proliferation of some types of cancer cell. However, the function of TRPM7 in the viability of breast cancer cells remains unclear. Here we show that TRPM inhibitors suppressed the viability of TRPM7-expressing breast cancer cells. We first demonstrated that the TRPM7 inhibitors 2-aminoethyl diphenylborinate (2-APB), ginsenoside Rd (Gin Rd), and waixenicin A preferentially suppressed the viability of human embryonic kidney HEK293 overexpressing TRPM7 (HEK-M7) cells over wildtype HEK293 (WT-HEK). Next, we confirmed the effects of 2-APB on the TRPM7 channel functions by whole-cell currents and divalent cation influx. The inhibition of the viability of HEK-M7 cells by 2-APB was not mediated by the increase in cell death but by the interruption of the cell cycle. Similar to HEK-M7 cells, the viability of TRPM7-expressing human breast cancer MDA-MB-231, AU565, and T47D cells were also suppressed by 2-APB by arresting the cell cycle in the S phase. Furthermore, in a novel TRPM7 knock-out MDA-MB-231 (KO-231) cell line, decreased divalent influx and reduced proliferation were observed compared to the wildtype MDA-MB-231 cells. 2-APB and Gin Rd preferentially suppressed the viability of wildtype MDA-MB-231 cells over KO-231 by affecting the cell cycle in wildtype but not KO-231 cells. Our results suggest that TRPM7 regulates the cell cycle of breast cancers and is a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.